Maozhen Tian
About Maozhen Tian
Maozhen Tian serves as the Senior Manager of Statistical Programming at Sangamo Therapeutics, Inc., a position he has held since 2020. He has extensive experience in statistical programming, having worked in various roles at Sangamo Therapeutics and other pharmaceutical companies.
Work at Sangamo Therapeutics
Maozhen Tian has been employed at Sangamo Therapeutics, Inc. since 2018, holding various positions within the statistical programming department. Currently, he serves as Sr Manager, Statistical Programming, a role he has held since 2020. Prior to this position, he worked as a Principal Statistical Programmer from 2019 to 2020 and as a Sr. Statistical Programmer from 2018 to 2019. His tenure at Sangamo Therapeutics reflects a progression of responsibilities and expertise in statistical programming.
Previous Experience in Statistical Programming
Before joining Sangamo Therapeutics, Maozhen Tian worked at BioMarin Pharmaceutical Inc. as a Clinical SAS Programmer from 2014 to 2017. His experience at BioMarin contributed to his skills in clinical data analysis and programming. Additionally, he was employed at VDA Consulting as a Clinical SAS Programmer from 2012 to 2014. These roles provided him with a solid foundation in statistical programming and clinical trial support.
Career Timeline
Maozhen Tian's career in statistical programming spans over a decade, beginning at VDA Consulting in 2012. He transitioned to BioMarin Pharmaceutical Inc. in 2014, where he worked for three years. In 2018, he joined Sangamo Therapeutics, where he has since advanced through multiple roles, culminating in his current position as Sr Manager, Statistical Programming.
Expertise in Statistical Programming
Maozhen Tian possesses extensive expertise in statistical programming, particularly in the context of clinical trials. His roles have involved the application of SAS programming techniques to analyze clinical data, ensuring compliance with regulatory standards. His experience across different companies has equipped him with a comprehensive understanding of the statistical programming landscape in the biotechnology and pharmaceutical sectors.